DermTech, Inc. - Common Stock (DMTK)

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company’s strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company.

DermTech, Inc. (NASDAQDMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously a DermTech employee, as inducements material to the employee’s entering into employment with DermTech, in accordance with Nasdaq Listing Rule 5635(c)(4).

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting. The peer-reviewed study entitled, “Non-invasive gene expression analysis rules out melanoma with high negative predictive value regardless of skin phototype” was presented at the Winter Clinical Dermatology Conference (January 12-17, 2024).

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024.

DermTech, Inc. (NASDAQDMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting.

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (NASDAQDMTK) on behalf of long-term stockholders following a class action complaint that was filed against DermTech on October 15, 2023 with a Class Period from May 3, 2022 to November 3, 2022. Our investigation concerns whether the board of directors of DermTech have breached their fiduciary duties to the company.

If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/DMTK.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQDMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”), of the important December 15, 2023 lead plaintiff deadline.

DermTech, Inc. (NASDAQDMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the grant to 15 new employees of restricted stock units representing the contingent right to receive up to an aggregate of 56,230 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The restricted stock units were approved by DermTech’s Compensation Committee, effective December 11, 2023, and were granted as inducements material to the employee’s acceptance of employment with DermTech in accordance with Nasdaq Listing Rule 5635(c)(4).

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DermTech, Inc. (“DermTech” or the “Company”) (NASDAQDMTK) securities between March 8, 2021 and November 3, 2022, inclusive (the “Class Period”).

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQDMTK) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired DermTech securities between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”). Investors have until December 15, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) --

NEW YORK, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQDMTK) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired DermTech securities between March 8, 2021 and November 3, 2022, both dates inclusive (the “Class Period”). Investors have until December 15, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

If you suffered losses exceeding $25,000 investing in DermTech stock or options between March 8, 2021 and November 3, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/DMTK.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQDMTK) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired DermTech securities between May 3, 2022 and November 3, 2022, both dates inclusive (the “Class Period”). Investors have until December 15, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.